Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Life Tables01:22

Life Tables

A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026
Same author

Finite depletion, sustained control: can impulse therapy prevent rebound activity in multiple sclerosis?

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Caution in interpreting disease-modification claims with lecanemab: Selective reporting and causal inference.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Thymic health under the microscope.

Nature·2026
Same author

Looking Beyond Dose: Identifying Responders and Non-Responders to RehaCom Computerized Cognitive Rehabilitation in Progressive MS-The CogEx Study.

Neurorehabilitation and neural repair·2026
Same journal

Teaching Video NeuroImage: Tardive Blepharoclonus.

Neurology·2026
Same journal

Teaching NeuroImage: Latent Axonal Degeneration in Patient With Anterior Circulation Stroke.

Neurology·2026
Same journal

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same journal

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same journal

Digital Semiology.

Neurology·2026
Same journal

Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

Neurology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Mortality in patients with multiple sclerosis.

Antonio Scalfari1, Volker Knappertz, Gary Cutter

  • 1Centre of Neuroscience, Division of Experimental Medicine, Department of Medicine, Imperial College, Hammersmith Hospital, London, UK.

Neurology
|July 10, 2013
PubMed
Summary
This summary is machine-generated.

Mortality is higher in multiple sclerosis (MS) patients. Treatment with interferon-β-1b significantly reduced mortality, showing its value in clinical trials for assessing long-term outcomes.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Related Experiment Videos

Last Updated: May 9, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Area of Science:

  • Neurology
  • Clinical Research
  • Epidemiology

Background:

  • Mortality in multiple sclerosis (MS) patients is significantly higher than in the general population.
  • Inconsistent study results regarding MS survival are attributed to varying data collection times, geographic locations, improved chronic care, and differing methodologies.
  • Factors like age at onset and disease course influence survival, while sex-related mortality data remains contradictory.

Purpose of the Study:

  • To address unanswered questions regarding survival and mortality in multiple sclerosis (MS).
  • To evaluate the impact of treatments on mortality as a long-term outcome in randomized controlled trials (RCTs).
  • To analyze causes of death in MS patients, including those not directly attributed to the disease.

Main Methods:

  • Review and synthesis of existing data on multiple sclerosis (MS) survival and mortality.
  • Analysis of factors influencing survival, including age at onset, disease progression, and sex.
  • Inclusion of data from long-term follow-up studies, such as those evaluating interferon-β-1b.

Main Results:

  • Multiple sclerosis (MS) is the primary cause of death in over 50% of patients.
  • Suicide rates are substantially increased in MS patients and should be considered an MS-related cause of death.
  • Treatment with interferon-β-1b demonstrated a significant reduction in mortality among treated patients.

Conclusions:

  • Mortality is a valid and significant long-term outcome in multiple sclerosis (MS) clinical trials.
  • Assessing mortality in MS trials can effectively combine the impact of treatment efficacy on longevity and adverse events.
  • Further research is needed to clarify contradictory findings regarding sex and mortality in MS.